Your browser doesn't support javascript.
loading
Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
Hill-Burns, Erin M; Debelius, Justine W; Morton, James T; Wissemann, William T; Lewis, Matthew R; Wallen, Zachary D; Peddada, Shyamal D; Factor, Stewart A; Molho, Eric; Zabetian, Cyrus P; Knight, Rob; Payami, Haydeh.
Afiliação
  • Hill-Burns EM; Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Debelius JW; Department of Pediatrics, University of California San Diego, La Jolla, California, USA.
  • Morton JT; Department of Computer Science and Engineering, University of California San Diego, La Jolla, California, USA.
  • Wissemann WT; Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Lewis MR; Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Wallen ZD; Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Peddada SD; Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA.
  • Factor SA; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Molho E; Department of Neurology, Albany Medical College, Albany, New York, USA.
  • Zabetian CP; Veterans Affairs Puget Sound Health Care System and Department of Neurology, University of Washington, Seattle, Washington, USA.
  • Knight R; Department of Pediatrics, University of California San Diego, La Jolla, California, USA.
  • Payami H; Department of Computer Science and Engineering, University of California San Diego, La Jolla, California, USA.
Mov Disord ; 32(5): 739-749, 2017 05.
Article em En | MEDLINE | ID: mdl-28195358
ABSTRACT

BACKGROUND:

There is mounting evidence for a connection between the gut and Parkinson's disease (PD). Dysbiosis of gut microbiota could explain several features of PD.

OBJECTIVE:

The objective of this study was to determine if PD involves dysbiosis of gut microbiome, disentangle effects of confounders, and identify candidate taxa and functional pathways to guide research.

METHODS:

A total of 197 PD cases and 130 controls were studied. Microbial composition was determined by 16S rRNA gene sequencing of DNA extracted from stool. Metadata were collected on 39 potential confounders including medications, diet, gastrointestinal symptoms, and demographics. Statistical analyses were conducted while controlling for potential confounders and correcting for multiple testing. We tested differences in the overall microbial composition, taxa abundance, and functional pathways.

RESULTS:

Independent microbial signatures were detected for PD (P = 4E-5), participants' region of residence within the United States (P = 3E-3), age (P = 0.03), sex (P = 1E-3), and dietary fruits/vegetables (P = 0.01). Among patients, independent signals were detected for catechol-O-methyltransferase-inhibitors (P = 4E-4), anticholinergics (P = 5E-3), and possibly carbidopa/levodopa (P = 0.05). We found significantly altered abundances of the Bifidobacteriaceae, Christensenellaceae, [Tissierellaceae], Lachnospiraceae, Lactobacillaceae, Pasteurellaceae, and Verrucomicrobiaceae families. Functional predictions revealed changes in numerous pathways, including the metabolism of plant-derived compounds and xenobiotics degradation.

CONCLUSION:

PD is accompanied by dysbiosis of gut microbiome. Results coalesce divergent findings of prior studies, reveal altered abundance of several taxa, nominate functional pathways, and demonstrate independent effects of PD medications on the microbiome. The findings provide new leads and testable hypotheses on the pathophysiology and treatment of PD. © 2017 International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Antagonistas Colinérgicos / Disbiose / Inibidores de Catecol O-Metiltransferase / Microbioma Gastrointestinal / Antiparkinsonianos Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Antagonistas Colinérgicos / Disbiose / Inibidores de Catecol O-Metiltransferase / Microbioma Gastrointestinal / Antiparkinsonianos Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2017 Tipo de documento: Article